Policy Briefings

SWHR regularly holds briefings on a variety of women’s health and research-related subjects. These briefings are attended by Congressional staff, federal agency personnel, advocacy group representatives and others to educate attendees about issues important to women’s health.

U.S. Presidential Election Letters

SWHR sent a letter congratulating the 2016 presidential election winner.

SWHR sent letters congratulating the 2016 presidential election nominees and urging them to make women’s health a priority in their platforms.

Congressional Testimony

As the thought leader in advocating for research on sex differences, SWHR is often called upon by Congressional Committees to offer expert testimony on a variety of subject areas. An archive of our past Congressional Testimony is below.

Written Testimony for Federal Funding

Policy Letters

As part of its advocacy mission, the Society for Women’s Health Research monitors the activities of the executive branch in the areas of women’s health and research. At the request of various federal agencies, SWHR periodically submits public comment letters detailing its positions on issues pertaining to SWHR’s public policy priorities.


  • SWHR sent a letter to the Centers for Medicare & Medicaid Services expressing concerns about its recent memorandum that allows Medicare Advantage plans to implement step therapy protocols to manage Part B-covered medications. (Oct. 5, 2018)
  • SWHR signed on to a congressional letter expressing appreciation for FDA’s detailed technical assistance on discussion draft legislation. (August 8, 2018)
  • SWHR submitted comments to the Food and Drug Administration (FDA) on its draft guidance on including pregnant women in clinical trials. (June 8, 2018)
  • SWHR submitted comments to the Institute for Clinical and Economic Review (ICER) on its draft evidence report on new therapies for endometriosis. (May 31, 2018)
  • SWHR signed on to a letter urging Congress to enact legislation to modernize oversight of clinical laboratory diagnostics. (May 9, 2018)
  • SWHR submitted comments to the Institute for Clinical and Economic Review (ICER) on its evaluation of calcitonin gene-related peptide (CGRP) inhibitors, a new class of preventive therapies for episodic and chronic migraine. (May 8, 2018)
  • SWHR issued comments to the Food and Drug Administration on Patient-Focused Drug Development. (February 16, 2018)
  • SWHR  Input on ICER 2018 Review of Endometriosis as Public Comment. (February 1, 2018)
  • SWHR is pleased to support the congressional resolution recognizing January 25 as Women’s Health Research Day. (January 19, 2018) 


View Past Policy Letters

Commentary Letters